A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy With Or Without Androgen Deprivation Therapy In Oligometastatic Prostate Cancer (NRG PROMETHEAN)

Date Added
June 6th, 2025
PRO Number
Pro00144873
Researcher
Brian Lally

List of Studies

Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

The purpose of this study is to determine if we lower the chance of your prostate cancer growing or spreading by adding the drug relugolix to the usual radiation therapy? This study seeks to find if this approach is better or worse than standard of care for prostate cancer.

Treatment and follow up for this study may be up to 5 years. The procedures include blood samples, PET scans, hormone therapy and radiation therapy. Risks include diarrhea, back pain, weight gain, and headache. You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Entirely Remote 2-Week Integrated Treatment for Pain and PTSD

Date Added
July 1st, 2025
PRO Number
Pro00144178
Researcher
Ronald Acierno

List of Studies

Keywords
Anxiety, Military, Pain
Summary

The purpose of this study is to see how well the combination of home-based transcranial direct current stimulation (tDCS) and prolonged exposure (PE) works in treating people with chronic pain (e.g., pain related to fibromyalgia, lower back pain, arthritis) and posttraumatic stress disorder (PTSD).

Participants must be a Veteran or Active-Duty service member with a diagnosis of PTSD and chronic musculoskeletal pain. Participants will receive 10 sessions of PE over 2 weeks (called Massed PE) and 10 sessions of tDCS.

Institution
MUSC
Recruitment Contact
Stephanie Hart
843-789-6519
zeigls@musc.edu



-- OR --